ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

The goal of this clinical trial is to investigate whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable ctDNA after surgery. The main research question the REACT study aims to answer is: \- Does adjuvant chemotherapy improve disease-free survival in patients with high-risk rectal cancer with detectable ctDNA after surgery? Interventions: \- Patients with detectable ctDNA after surgery and randomised to the experimental group will be offered adjuvant chemotherapy (4 cycles CAPOX/6 cycles FOLFOX) within 12 weeks after surgery.

NCT Number	NCT07188025
Lead Sponsor	Erasmus Medical Center Collaborators: Prospectief Landelijk CRC Cohort (PLCRC), Dutch Colorectal Cancer Group (DCCG), BOOG Study Center
Conditions	Rectal Cancer
Enrollment	103 participants
Start Date	2025-10-14
Primary Completion	2030-10 (estimated)
Study Completion	2035-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-09